SEC Tracker
Get the app
GRCE · XBRL financial data

Grace Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (GRCE's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development4601,4431,685*2,7082,9762,1941,634*955568462420*697
General and administrative1,5891,5701,510*2,2551,8551,5101,549*2,1351,9611,9872,590*1,687
Operating income (loss)(2,092)(3,043)(3,263)*(4,963)(4,831)(3,704)(3,183)*(3,090)(2,529)(2,449)(3,010)*(15,917)
Interest income212316249*235172138167*205172170138*141
Income tax expense (benefit)(446)(208)(889)*(724)(852)(605)(1,018)*000(1,700)*0
Net income (loss)(3,273)(2,391)(3,166)*(2,617)(3,432)(4,155)636*(3,362)(938)(2,315)(1,178)*(15,790)
Earnings per share, basic USD per share(0.43)(0.21)—(0.24)(0.30)(0.36)—(0.21)(0.06)(0.14)(0.07)*(0.91)
Earnings per share, diluted USD per share(0.43)(0.21)—(0.24)(0.30)(0.36)—(0.21)(0.06)(0.14)(0.07)*(0.91)
Weighted average shares, basic thousands of shares7,55311,50611,622*10,92911,50611,50614,447*15,92515,92516,93417,270*17,270
Weighted average shares, diluted thousands of shares7,55311,50611,622*10,92911,50611,50614,447*15,92515,92516,93417,270*17,270

Balance sheet

CSV

Fiscal quarters (GRCE's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,99118,54523,00519,39415,15511,05522,13320,00516,86218,67216,97713,756
Short-term investments156,56901515———————
Accounts receivable837959722398————————
Total current assets28,88726,88424,01020,42916,06211,93922,71220,52517,29819,21117,38014,333
Property and equipment, net——24———15———8—
Right-of-use asset47230—————————
Goodwill8,1388,1388,1388,1388,1388,1388,1388,1388,1388,1388,1388,138
Total assets78,21076,18573,30069,71865,34961,22471,99369,80566,57668,48866,65450,073
Accrued liabilities460532176814————————
Total current liabilities1,3971,7701,6842,6002,6741,9711,9302,3151,2451,2842,1461,250
Lease liability, non-current000—————————
Total liabilities11,46511,50511,55710,3549,2159,0855,3836,2553,7583,5962,7581,862
Accumulated deficit(205,562)(207,953)(211,119)(213,736)(217,168)(221,323)(220,687)(224,049)(224,987)(227,302)(228,480)(244,270)
Total stockholders' equity66,74564,68061,74359,36456,13452,13966,61063,55062,81864,89263,89648,211
Total liabilities and equity78,21076,18573,30069,71865,34961,22471,99369,80566,57668,48866,65450,073
Common shares outstanding (cover page) thousands of shares9,3999,3999,39910,14010,14010,14013,82913,82914,12915,47416,27421,036

Cash flows

CSV

Fiscal quarters (GRCE's year ends in late March)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(3,273)(2,391)(3,166)*(2,617)(3,432)(4,155)636*(3,362)(938)(2,315)(1,178)*(15,790)
Stock-based compensation280*326*229*238202*160*130*302206*108*182*105
Net cash from operating activities(2,113)*(1,892)*(2,088)*(3,596)(4,239)*(4,115)*(2,954)*(1,801)(3,143)*(2,230)*(1,695)*(3,221)
Net cash from investing activities110*(6,554)*6,548*(15)0*15*0*00*0*0*—
Proceeds from issuing common stock0*0*0*—————————
Net cash from financing activities7,359*0*0*00*0*14,032*(327)0*4,040*0*0
Net change in cash5,358*(8,446)*4,460*(3,611)(4,239)*(4,100)*11,078*(2,128)(3,143)*1,810*(1,695)*(3,221)

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Grace Therapeutics13,756not reported(3,221)21.0M4.3 quarters 10-QJun 30, 2026
Annovis Bio18,7290*(21,914)*42.6M0.9 quarters 10-QJun 30, 2026
Abvc Biopharma32not reported(244)*26.7M0.4 quarters 10-QJun 30, 2026
Karyopharm Therapeutics54,98033,432(24,931)*22.7M2.6 quarters 10-QJun 30, 2026
Kezar Life Sciences66,229not reported(7,445)7.4M8.9 quarters 10-QMar 31, 2026
BriaCell Therapeutics9,852not reported(5,959)*8.7M3.4 quarters 10-KJul 31, 2026
Insight Molecular Diagnostics17,756239(9,268)*32.7M1.9 quarters 10-QJun 30, 2026
Rein Therapeutics8,5420(8,640)*86.3M4.7 quarters 10-QJun 30, 2026
Yarrow Bioscience22,92597(1,992)*2.7M11.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.